No Data
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Study
60 Degrees Pharmaceuticals Shares Are Trading Higher After the Company Announced the First Patient Enrollment for Its Tafenoquine Expanded Access Study for Persistent Babesiosis.
Express News | 60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. Microti) Babesiosis
Analysts Offer Insights on Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP), Ionis Pharmaceuticals (IONS) and Zura Bio (ZURA)
Express News | HC Wainwright & Co. Reiterates Neutral on 60 Degreesto Neutral
60 Degrees Pharmaceuticals, Tufts Medical Center Sign Patent License Deal Over Potential Babesiosis Treatment
No Data
ProperMicheleV : u r 100% correct. Tanefoquine is not the answer to chronic babesiosis. However, this company is somehow connected to the CDC & important legislators in DC. Their HQ is located steps away from all the important pharma players in DC & the senate. That being said, at some point, after Yale, Tufts & NC college of Veterinary Medicine, publish the pps will
. We all know those academic institutions are paid to provide answers that benefit whose paying them, not only by corrupt grants but flat fees for their research. Long story short.... they have a dog in the fight. There should be laws against that. If I give 250k to Harvard Business Review, I can get a ham sandwich in pill form touted as the next "cure all". There is total catastrophic failure on the horizon. & I feel GSK is still involved with Tanefoquine aka Krintafel. Google it.